Framatome has established a new member of its brand family, Framatome Healthcare. The move builds on the company's nuclear energy expertise and long-standing commitment in the field of nuclear medicine to advance medical products and services for the healthcare industry.

Complementing its expertise in the nuclear energy industry, and continuing its current efforts in the medical field, Framatome provides a variety of products and services devoted to medical applications and cancer-fighting treatments. Activities under the new brand include work with medical professionals to provide irradiation targets - a byproduct of nuclear technology. Additionally, Framatome designs and produces medical radioisotope activation systems, specialized alloys used in the manufacturing of surgical implants, and industrial and medical sterilization systems.

"By mobilizing Framatome Healthcare, we are strengthening our activities in the field of nuclear medicine and medical equipment," said Bernard Fontana, CEO of Framatome. "We are proud to be part of the development of a robust supply chain together with our customers, suppliers and partners. We are fully committed to join utilities, research reactor operators, radiopharmaceuticals and healthcare companies, in making important lifesaving medical treatments available to patients around the world."

What is the connection between Framatome and healthcare?
Framatome's healthcare efforts play a critical role supporting the value chain for the radioisotopes used in radiopharmaceuticals for diagnostic imaging and for therapeutic purposes. CERCA, a division of the Framatome Fuel Business Unit, is the world's leading supplier of uranium fuel and targets for research reactors. The targets, once irradiated in a research reactor and following chemical extraction, enable the production of radioisotopes (Molybdenum-99/Technetium-99m, Xenon-133 and Iodine-131) used in hospitals for the diagnosis and treatment of cancers.

In February 2020, Framatome and Kinectrics announced the launch of Isogen, a joint venture to produce medical isotopes for lifesaving cancer treatment. Isogen specializes in producing medical radioisotopes in commercial Candu power reactors without interrupting safe, reliable, clean energy generation. In partnership with Bruce Power, Isogen produces medical isotopes used to treat and diagnose patients with serious diseases. The first production systems installed by Isogen will produce Lutetium-177, a promising medical radioisotope used in several cancer treatments.

Framatome's metallurgical processing capabilities enable it to supply manufacturers of surgical implants and prostheses with special alloys.

The company also possesses a wide knowledge in design, layout, and modernization of complex facilities with irradiation sources such as sterilization facilities, essential for the use of medical materials (gamma irradiation).

Related Links
Framatome
Nuclear Power News - Nuclear Science, Nuclear Technology
Powering The World in the 21st Century at Energy-Daily.com

Tweet

Thanks for being here; We need your help. The SpaceDaily news network continues to grow but revenues have never been harder to maintain. With the rise of Ad Blockers, and Facebook - our traditional revenue sources via quality network advertising continues to decline. And unlike so many other news sites, we don't have a paywall - with those annoying usernames and passwords. Our news coverage takes time and effort to publish 365 days a year. If you find our news sites informative and useful then please consider becoming a regular supporter or for now make a one off contribution.
SpaceDaily Contributor $5 Billed Once credit card or paypal		SpaceDaily Monthly Supporter $5 Billed Monthly paypal only

Framatome's first reload of GAIA fuel installed in a US reactor
Paris, France (SPX) Jul 14, 2021
The first reload of Framatome's GAIA fuel has been installed in a U.S. pressurized water reactor (PWR). Manufactured at Framatome's fuel fabrication facility in Richland, Washington, 64 fuel assemblies were loaded into the reactor as part of a standard spring refueling outage. "This first reload of GAIA in the U.S. represents a significant milestone in Framatome's innovations that provide increased flexibility and fuel efficiency for our customer's operations," said Lionel Gaiffe, senior executive ... read more